NACDS Defines “PBM Reform” for Senate Hearing Statement outlines specific solutions to patient-manipulation by “PBMs”
Statement outlines specific solutions to patient-manipulation by “PBMs”.
Statement outlines specific solutions to patient-manipulation by “PBMs”.
While we all want to move on from COVID-19, doing so should not mean leaving behind millions of Americans who have relied on their trusted, local pharmacies for testing, vaccinations, and care during the pandemic.
Event opens NACDS’ 90th anniversary celebration; brings together pharmacy chains with between four and 250 locations and their supplier partners.
NACDS’ engagement leverages bipartisan momentum for pro-patient, pro-pharmacy PBM reform at state and federal levels.
NACDS: Floridians, all Americans deserve better than the current “pharmaceutical benefit manipulation”
It is a two-year anniversary that patients and pharmacies can appreciate. With a unanimous decision on December 10, 2020, the U.S. Supreme Court upheld an Arkansas law that confronts the damaging tactics of prescription-drug middlemen known as pharmacy benefit managers (PBMs). NACDS had submitted an amicus brief in this case, Rutledge, Attorney General of Arkansas v. Pharmaceutical Care Management Association (PCMA).
Continues momentum in Tennessee and nationwide to advance patients’ health, convenience, and savings by confronting PBM tactics.
The National Community Pharmacists Association (NCPA), the American Pharmacists Association (APhA), the National Association of Chain Drug Stores (NACDS), the Oklahoma Pharmacists Association (OPA) and American Pharmacies (APRx) issued the following joint press release today.
Last week, NACDS took issue with an op-ed in The Wall Street Journal titled, “In Defense of Pharmacy Benefit Managers (PBMs),” which asserted that “swarms of drug-company lobbyists appear to have united both parties in opposition to [PBMs]” and that PBMs – unreasonably – “are taking the blame for high drug prices.”
On July 8, Florida Governor Ron DeSantis issued an Executive Order “to drive transparency in prescription costs for Floridians.